perpetuity. It is made available under a CC-BY-ND 4.0 International license .

1

2

3

4

5

6

7 8 9

10 11

12

Diagnostic Utility of Electrophysiological Markers for Early and Differential Diagnosis of Alzheimer's, Frontotemporal, and Lewy Body Dementias: A Systematic Review

Stéphanie De Keulenaer¹, Sara Van Mossevelde^{1,2}, Tobi Van den Bossche^{1,2}, David Crosiers^{1,2}, Patrick Cras^{1,2,3}, Tommas Ellender¹, Rose Bruffaerts^{1,2}

¹ University of Antwerp (Uantwerpen), Belgium ² University Hospital of Antwerp (UZA), Belgium ³ IBB-Neurobiobank, Antwerp, Belgium

Abstract

13 Background

14 An early and accurate diagnosis is crucial to provide optimal patient care in neurodegenerative

15 diseases. Although an EEG shows advantages in availability and cost compared to the current

16 diagnostic tools, it is not routinely used in clinical practice. Previous reviews have either focused on

17 single disease populations and/or solely on resting state EEG. To evaluate the utility of EEG for early

18 diagnosis and differential diagnosis, we conducted a systematic review across Alzheimer's disease

19 (AD), Frontotemporal Dementia (FTD) and Lewy Body Dementia (DLB).

20 Methods

21 We searched databases Pubmed, Cochrane, Web of Science, and Scopus for articles published from

22 2000 to 2023 investigating resting-state and task-based EEG-markers in biomarker-proven AD, FTD23 and DLB.

24 Results

25 Our search yielded a total of 12010 studies, of which 71 papers were eligible: 34 on AD, 18 on DLB

and 9 on FTD. Slowing of the frequency spectrum was a common observation across diseases,

27 achieving excellent sensitivity in AD and DLB. Research on FTD was limited and with varying results

in the discrimination from healthy controls, although connectivity analysis and microstates are

29 promising avenues. In differential diagnosis, both spectral and connectivity metrics show encouraging

30 results. Task-based EEG emerges as a promising tool in early AD.

- 31
- 32 Conclusion
- EEG shows promise as a cost-effective, non-invasive tool for early detection and differential
- 34 diagnosis. Future research should aim to collect standardized data from multicentric cohorts, across
- 35 multiple diseases and stages, and explore the neural underpinnings of these diseases, to improve
- 36 interpretability of the findings.
- 37 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Corresponding author: Rose Bruffaerts, University of Antwerp (UAntwerpen), Universiteitsplein 1, 2610, Wilrijk, Belgium, rose.bruffaerts @uantwerpen.be

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

38

Introduction

39 The estimated global prevalence of dementia in 2019, 57.4 million cases, is predicted to show a 166%

- 40 increase by 2050 due to population growth and ageing [1]. Alzheimer's Disease (AD) is the most
- common type, representing 60-70% of dementia cases, followed by Frontotemporal Dementia (FTD)
- 42 and Lewy Body Dementia (DLB). One of the critical challenges in dementia, is an early and accurate
- 43 diagnosis of neurodegenerative disease. Early detection is crucial for management of the disease and
- the effectiveness of disease-modifying therapies [2]. However, several issues complicate diagnostic
 accuracy. First, conventional structural diagnostic tools such as magnetic resonance imaging (MRI)
- 46 and computer tomography (CT) are not sensitive to metabolic and functional alterations in the brain,
- 47 occurring years before clinical onset ([3]). Second, traditional diagnostic tools are lacking in disease
- 48 specificity, in particular when faced with syndromes high in clinical overlap. Last, cerebrospinal fluid
- 49 (CSF) biomarkers and positron emission tomography (PET) scans, are valuable in providing insights
- 50 in underlying pathology but are costly, invasive and not widely-accessible. As an alternative,
- electroencephalography (EEG) has emerged as a non-invasive, widely-accessible and cost-effective
- 52 tool in the search for reliable biomarkers. EEG measures neuronal activity at high temporal resolution,
- allowing detection of early functional changes associated with ageing and neurodegeneration,
- 54 delivering unique insights in the effects of neuropathology on neurophysiological mechanisms
- 55 underpinning cognitive functioning.
- 56 In AD, the utility of resting state EEG (rsEEG) rhythms in wakefulness (eyes open or eyes closed)
- 57 have been studied as candidate biomarkers, as they are non-invasive, cost-effective and do not require
- the performance of tasks, tackling problems with fatigue and motivation. Compared to healthy
- 59 controls (HC), AD patients show slowing, i.e. the leftward shift in the power spectrum from higher (α ,
- 60 β, and γ) towards lower frequencies(δ and θ), as well as alterations in connectivity, complexity and
- 61 synchronization of neural activity [4]. An alternative approach is task-based EEG, providing insights
- 62 into the amplitude and latency of neural responses or event-related potentials (ERP) elicited by
 63 different cognitive tasks. A recent systematic review highlights reduced amplitude and delayed latency
- 64 in AD compared to healthy controls in various well-known ERP components such as the P300 and
- 65 N400 [5]. However, heterogeneity in the AD samples and study paradigms, along with scarcity of
- reported effect sizes, complicates meta-analyses across both resting-state EEG [4] as task-based EEG
- 67 studies [5].Furthermore, diagnostic criteria have advanced from traditional neuropsychological and
- 68 clinical measures to the inclusion of biomarkers, improving diagnostic accuracy in research studies
- 69 and enhancing the reliability of research outcomes.
- 70 Another issue is the differential discrimination between neurodegenerative diseases. The differential 71 diagnosis in early stages is suboptimal, for instance in discriminating DLB from AD. In the most 72 recent consortium on diagnostic criteria, posterior slow-wave activity showing periodic fluctuations 73 within the pre- α/θ range in resting-state EEG was recognized as a supportive biomarker for DLB [6]. 74 From a recent systematic review, over 90% of DLB patients have diffuse EEG abnormalities [7]. 75 Although EEG slowing was found to be more severe in AD compared to DLB, EEG abnormalities 76 related to DLB overlap with those found in other neurodegenerative diseases such as AD. Just as in 77 AD studies, previous systematic reviews in DLB have addressed issues such as preliminary sample
- sizes with large heterogeneity in patient cohorts, and lack of standardization in EEG protocols and
 reporting, complicating the identification of the optimal feature for differential diagnosis [7, 8]
- 80
- In FTD research, studies have pursued similar aims of improving diagnosis with EEG, showing
 slowing of the power spectrum [9, 10]. However, the scarcity of studies in FTD results in too little
 evidence to reach consensus.
- 84

Although numerous studies have been conducted on the use of EEG in AD, FTD and DLB, no

- 86 comprehensive review has yet compared EEG results across neurodegenerative diseases. Addressing
- 87 this gap is crucial to define the specificity of electrophysiological markers in the differential diagnosis.

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Additionally, to evaluate the utility of EEG in early stages of the diseases, we are interested in the preclinical and prodromal stages of the diseases. In line with the current diagnostic standards, we include exclusively biomarker-proven stages of AD [11]. To summarize the available literature, we conducted a systematic search on publications studying EEG-markers across AD, FTD, DLB and/or

92 their preclinical and prodromal phases, compared to healthy controls.

93 94

Methods

95 The review was prospectively registered in PROSPERO (ID: CRD42023392253). We performed a

systematic search using online databases Pubmed, Cochrane, Web of Science and Scopus for English
 articles published from 2000 to January 2023. The full search strategy is provided in supplementary

- 98 material (S1).
- 99
- 100 Screening

101 Our search yielded a total of 12010 studies. The online collaboration platform Rayyan

102 (https://www.rayyan.ai/) was used to implement, deduplicate and screen articles. Possible duplicates

as detected by Rayyan were manually checked. Following deduplication, 6952 abstracts were screened

104 for eligibility based on inclusion and exclusion criteria by two independent researchers (SDK, RB)

blinded to each other's rating. Based on abstract only, 6243 articles were excluded. The remaining 709

- 106 potential eligible articles were then screened on full text based on the same inclusion and exclusion
- 107 criteria. The main reason of exclusion was not including biomarkers in AD (n=476). Conflicts were
- 108 resolved by discussion between the researchers. The PRISMA flowchart (Figure 1) shows the full
- 109 screening and exclusion process.
- 110 Inclusion criteria:
- Participant population: AD, FTD, DLB, including preclinical and prodromal stages, 111 presymptomatic carriers of genetic causative mutations and healthy controls. In line with the 112 International Working Group 2 (IWG-2) criteria for AD, we only include biomarker-proven 113 114 cases of AD showing in vivo evidence of amyloid and tau pathology [12], presymptomatic carriers of familiar AD (FAD) by Amyloid Precursor Protein (APP) and Presenilin 115 (PSEN1/PSEN2) causative mutations were included. Criteria for FTD diagnosis were a 116 117 diagnosis following the Rascovsky criteria for bvFTD [13], Gorno-Tempini criteria for PPA[14], carrier of a genetic mutation of FTD, and/or imaging evidence of frontotemporal 118
- atrophy. DLB was defined by the criteria of McKeith [6, 15].
- 120 Primary research studies
- 121 English language
- 122 Studies using resting-state EEG and/or task-based EEG as neuroimaging modality
- 123 Exclusion criteria:
- Studies that combine multiple neuroimaging modalities or EEG with other biomarkers but do
 not separately report the performance of EEG markers.
- 126 Animal studies
- 127 Population with comorbidities (Down Syndrome, Schizophrenia, ...)
- 128 Prognostic studies
- 129 Case studies or study population <5 participants
- 130 Sleep EEG
- Lastly, risk of bias was assessed using a hybrid version of the Joanna Briggs Institute (JBI) CriticalAppraisal checklist (supplementary material S2).
- 133
- 134

perpetuity. It is made available under a CC-BY-ND 4.0 International license .



168 Figure 1. PRISMA flowchart diagram for systematic reviews [16].

169 *Data extraction:*

170 The following data was extracted manually from eligible studies. Tables with data can be

- 171 found in supplementary material (S3).
- 172 1. Article information: First author, year
- 173 2. Study population: Sample size, patient population(s), control group(s), biomarkers
- 174 3. EEG acquisition: number of electrodes, sampling frequency, recording state
 175 (resting/task-based), duration
- 176 4. Analysis
- 177 5. Reported results
- 178 *Data synthesis:*
- 179 As our field of interest includes a heterogenous group of pathologies and disease stages as
- 180 well as various recording and analysis conditions, data is presented descriptively. AUROC
- 181 characteristics, sensitivity, specificity and diagnostic accuracy were reported if provided.

182

Results

183 Study characteristics

184 Our search yielded a total of 6957 unique studies, of which 71 studies were included in the final 185 review (figure 1). In total, we included 34 AD studies, 9 FTD studies, 18 DLB studies, and 9 studies combining disease populations. The studies included a total of 1115 patients with dementia due to 186 biomarker-proven Alzheimer (demAD) and 915 prodromal AD (prodAD) cases. Seven studies 187 included preclinical AD pathology by positive amyloid and/or tau biomarkers (n=397). Six studies 188 189 included FAD (n=43) and/or prodromal FAD (prodFAD, n=22) and asymptomatic carriers of a PSEN 190 1 or APP mutation (AcrFAD, n=100). Four studies included patients with bvFTD (n=108), three 191 studies included not specified FTD (n=38). One study included familiar CHMP2B-FTD symptomatic (n=5) and presymptomatic carriers (n=5). One study compared non-fluent variant PPA (n=18), 192 semantic variant PPA (n=10) and logopenic variant PPA (n=12). 18 studies included DLB patients 193 194 (n=589), while only one study focused on prodDLB (n=21). In case studies included DLB or FTD 195 combined with non-biomarker proven AD, only the results of the FTD or DLB patients are described. 196 Five studies compared prodAD (n=111) and prodDLB (n=111), while one study included demAD 197 (n=66) and DLB (n=66). Two studies using the same dataset compared PPA (n=5), bvFTD (n=13) and prodAD (n=18), a third study compared bvFTD (n=48) to AD (n=69). The majority of the studies 198 199 employed a rsEEG recording (figure 2c). All of studies combining different disease populations employed resting state EEG. 200



203

Figure 2. a) Study characteristics in studies including a single patient population. b) Study characteristics comparative studies. c) Percentage of studies using rsEEG or tbEEG per population. AD= Alzheimer's Disease, prodAD= prodromal AD, preAD=preclinical ADFAD= Familial AD, prodFAD= prodromal FAD, ACR FAD= asymptomatic carriers of a FAD causative mutation, FTD= frontotemporal dementia, bvFTD= behavioral variant FTD, CHMP2B-FTD= symptomatic CHMP2B carriers, CHMP2B-FTD Acr= asymptomatic CHMP2B carriers, nfvPPA= non-fluent variant primary progressive aphasia (PPA), svPPA= semantic variant PPA, lvPPA= logopenic variant PPA, DLB= Dementia with Lewy Bodies, prodDLB= prodromal DLB, rsEEG= resting-state EEG. tbEEG= task-based EEG

perpetuity. It is made available under a CC-BY-ND 4.0 International license.

209 Potential for AD diagnosis

210 Resting state EEG

211 Diffuse slowing of the frequency spectrum towards lower frequencies is a consistent observation in both prodAD [17–20] and demAD [21, 22]. The shift in the power spectrum in demAD manifests as 212 213 reduced spectral metrics in the α band, while spectral power in θ band increases [22]. Smailovic found that low a global field synchronization (GFS), a measure of global functional connectivity in the 214 215 frequency domain, is linked to abnormal A β 42 levels in demAD and prodAD, and high levels of p-tau 216 and t-tau in prodAD [23]. Secondly, in demAD, high levels of p-tau and t-tau correlate with low global 217 strength of scalp potential (GFP) in β and δ bands. In prodAD, high GFP in δ and θ was linked to 218 abnormal CSF levels of A β 42, while lower GFP α and β is linked to increased p-tau and t-tau. These 219 results are in line with the research of Cecchetti, showing that prodAD show higher θ density than 220 MCI without AD pathology with over 75% sensitivity and 70% specificity [21]. Similarly, Rodriguez 221 demonstrated that frontotemporal alterations in β band discriminate between presymptomatic PSEN1 carriers and noncarriers and between FAD and HC (see figure 3)[24]. Additionally, significant 222 223 progressive alterations in bispectral metrics are found along the AD continuum [25]. Specifically, with 224 increasing severity, interactions between the δ and θ bands and other bands increase, while interactions 225 with high frequency bands α , $\beta 1$, and $\beta 2$ bands diminish. Similarly, synchronization measures 226 demonstrate reduced functional connectivity in demAD in α and β bands, while coherence metrics in θ 227 band increase [26]. These results are similar to findings by Revilla-Vallejo, where Shannon Entropy 228 (SE) shows higher values in the δ band and lower values in the α and β 1 bands in prodAD and demAD 229 compared to HC, suggesting less connectivity and integration in these two bands [27]. 230

231 Another way to look at resting-state activity is through microstate analysis. Spontaneous resting state 232 activity can be described using microstates, transient global patterns of scalp potential, reflecting 233 coordination of neural activity among networks [28]. Microstate analysis in AD reveals alterations in 234 the duration, occurrence and coverage of microstates varying with severity. Specifically, demAD 235 patients showed a longer duration in microstate B [29]. In the study of Smailovic, topographic 236 differences in microstates A and D were found between HC and patient populations SCD, prodAD and 237 demAD [30]. Furthermore, preclinical and prodromal AD could be differentiated from the dementia stage by topographical differences in microstate A. The authors further found that topographical 238 239 alterations in microstate C were linked to increased Aβ42 levels, while p-tau levels were linked to microstate B alterations. 240

241

Recently, a number of studies used EEG-based machine learning classifiers for the detection of AD. 242 243 An advantage of these studies is that the outcome measures offer more insight into the potential 244 clinical implementation, which necessitates robust results at the individual level, compared to the prior 245 studies which reported results from group-level comparisons. Studies discriminating AD from HC 246 show promising classification accuracies in demAD ranging from 78% to 91% and in prodAD ranging 247 from 73-85% (see figure 3). Another measure of the model's accuracy is the F1 score, which is 248 calculated using precision (positive predictive value) and recall (true positive rate). Studies achieved 249 encouraging F1 scores ranging from 0.86 to 0.88 [31, 32]. Regarding the age factor, Durongbhan [33] 250 found encouraging results in discriminating demAD from HC below the age of 70 (sensitivity >90%, 251 specificity >83%), in individuals over 70 years, results were a little lower (>67% sensitivity, >85% specificity). Zhao studied both linear and nonlinear synchronization and found age- and disease-related 252 253 differences in network synchronization [34]. Healthy individuals below 70 years old exhibit 254 widespread linear synchronization with dynamic variability between eves closed (EC) and eves open 255 (EO) states, while in young individuals with demAD, this dynamic variability is diminished, indicating 256 network dysfunction. Secondly, they found a high widespread nonlinear synchronization during EO 257 with higher dynamic variability compared to demAD. In individuals above 70, both HC and demAD 258 showed similar levels of linear and nonlinear synchronization with minimal variability between states. 259 Combining linear and nonlinear connectivity yields highest classification accuracies below the age of 260 70 (80.3% EO, 74.5% EC) and above the age of 70 (EO 86.5%, EC 90.5%). 261

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

In preAD, PSD patterns can be used to model compensatory mechanisms and progression to AD [35]. 262 263 More specifically, individuals with amyloid burden in absence of neurodegeneration evidenced by 264 brain metabolism in AD core regions, show increased functional connectivity in the parieto-occipital α band. In individuals with neurodegeneration, the impact on EEG metrics varies depending the degree 265 266 of amyloid accumulation. More specifically, surpassing a critical threshold of amyloid accumulation, 267 reverses the compensatory upregulation of higher β and γ frequencies and decreased δ power seen in 268 intermediate amyloid burden, resulting in decreased β and γ power, MSF, spectral entropy, complexity 269 and wSMI in θ band while δ power increases. In individuals with subjective complaints (SCD) with 270 amyloid burden, Shim observed similar patterns of increased δ power in parietal, occipital and 271 posterior cingulate regions combined with decreased a activity in fusiform and inferior temporal areas[36]. In predicting AD pathology in individuals with SCD, the best ML model shows 88.6% 272 273 accuracy (see figure 3)[37].

274

275 Task-based EEG

276

277 A first important domain affected in AD is encoding and memory. Tautvydaite [38] shows that demAD patients show neural deficits in novelty detection and encoding during both learning and 278 delayed memory recognition of pictures. Specifically, demAD patients show a decreased P200 279 response to new and repeated items, reflecting attention and perceptual processing, as well as an 280 increased P300 during delayed repetition, which might reflect difficulties differentiating new from 281 familiar stimuli. Similarly, in a passive picture recognition task of Stothart [39], demAD patients 282 283 showed a decreased neural response to familiar pictures. Early differences in visual short term memory have also been found by Pietto[40] showing a reduced N1, P2 and P3 in prodFAD. Several studies 284 285 including asymptomatic carriers of an AD causative genetic mutation, explored the potential of task-286 based EEG for early detection, highlighting early neural functional alterations without corresponding 287 behavioral impairments. Golob [41] observed that presymptomatic carriers of the PSEN1 or APP mutation (mean age = 33.9), show discriminable neural alterations during an auditory target detection 288 289 task. These alterations included decreased slow wave amplitudes, increased P200 amplitude, and 290 delayed N100, N200, P200 and P300 latencies. Comparison of latencies across the ERP components showed that the latencies in the asymptomatic carriers were around 10% longer than the noncarrier 291 292 group. Nontarget P200 latency emerged as a potent discriminator, successfully identifying 87% of the 293 presymptomatic carriers. Quiroz [42] observed that during a recognition memory task, 294 presymptomatic PSEN1 carriers showed lower frontal ERP positivity alongside an increased occipital positivity, with 72.7% sensitivity and 81.8% specificity discrimination. Despite these neural 295 differences, both groups performed equally well on the task. Control subjects during recognition 296 297 memory, exhibited activation patterns reliably associated with frontally mediated processes 298 distinguishing between studied and unstudied visual items. PSEN1 carriers on the other hand, showed 299 increased brain activity in occipital regions associated with visual perceptual processing. Ochoa [43] 300 demonstrated a higher connectivity during the encoding condition of the same recognition memory 301 paradigm in PSEN1 presymptomatic carriers compared to non-carriers. Connectivity in the occipito-302 parietal region during the same memory encoding condition within the 500-600ms time window is 303 able to differentiate between presymptomatic and non-carriers with 67 % sensitivity and 80 % specificity [44]. P300 latency during an auditory oddball paradigm correlates with CSF levels of p-304 305 tau181, p-tau199 and ptau231 across demAD, prodAD and HC, while N200 latency negatively correlates with A\beta42 [45]. Recent studies in preAD using a working memory paradigm point towards 306 307 reduced α event-related desynchronization (ERD) and altered α spectral entropy, suggesting 308 compensatory hyperactivity during low load and insufficient cognitive resources with increasing work 309 load [46, 47]. In the γ band, low working load induces a higher low γ in preAD, while decreases in γ are observed during high load [48]. 310

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

- 312 In the **language domain**, sources of ERPs during a semantic-matching task reveal distinct
- topographical patterns in presymptomatic carriers versus non-carriers, although their behavioral
- responses and N400 amplitudes remain similar [49]. Specifically, presymptomatic carriers show a
- notable decrease in N400 generator strength within the right inferior-temporal and medial cingulate
- areas, and an increase within the left hippocampus and parahippocampus compared to non-carriers.
- 317 The observed shift in N400 distribution mirrored that seen in symptomatic carriers, albeit with a less
- 318 pronounced reduction in generator strength.

Study	Study population	EEG acquisition	AUC	Sen	Spe	Acc
Cao, 2022	demAD	rsEEG				0.86
Durongbhan, 2019	demAD	rsEEG		0.93	0.89	0.90
Maturana- Candelas, 2019	demAD	rsEEG		0.88	0.52	0.79
Zhao, 2019	demAD	rsEEG				0.91
Babiloni, 2017	prodAD	rsEEG	0.79	0.71	0.75	0.73
Kim, 2021	preAD			0.86	0.89	0.89
	prodAD			0.83	0.86	0.85
Arakaki, 2022	preAD	tbEEG	0.73			
Suarez-Revelo, 2016	AcrFAD	tbEEG		0.67	0.80	
	prodFAD			0.83	0.67	
Quiroz, 2011	Acr	tbEEG		0.73	0.82	
Rodriguez, 2014	Acr	rsEEG	0.90			
	FAD		0.99			
Golob, 2009	FAD	tbEEG				0.87

³¹⁹

Figure 3. AUROC values in AD studies. If multiple values were provided, only the highest value was reported. Studies were organized according to subpopulation. AD=Alzheimer's Disease, prodemAD= prodromal AD, preAD= preclinical AD, Acr = Asymptomatic carriers, prodFAD= prodromal Familial AD, FAD= Familial AD, rs-EEG= resting-state EEG, tbEEG= task-based EEG, AUC= Area under the curve, Sen=sensitivity, Spe= specificity, Acc= accuracy

324 Potential for FTD diagnosis

325 *rsEEG*

326 Spectral analysis in FTD shows a consistent slowing of the frequency spectrum. While studies agree 327 on a slowing in α frequencies, there is some discrepancy regarding the changes in the β band, with

some indicating a decrease and others suggesting an increase [9, 50]. In the study of Herzog [51],

329 hypoconnectivity in the δ band between frontal, temporal, parietal and posterior areas emerged as the

most relevant EEG feature, showing excellent AUC values in the discrimination of bvFTD from HC

331 (figure 4). One study found right frontotemporal hypoconnectivity in bvFTD, which correlated with

deficits in a naturalistic social text task [52].

333 Microstates were investigated in two studies. One study found that microstate duration C was

decreased in FTD and that the sequence of activation from C to D was reversed [53]. Another study

found that microstates vary with disease progression, showing an initial increase in microstate D, and

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

a decrease as disease duration prolongs in CHMP2B-FTD [54]. These conflicting results could be 336 337 explained by the different stages and variants of FTD. More specifically, microstate C is linked to the 338 insular-cingulate network, linked to changes in personality typical of bvFTD. In contrast, CHMP2B-339 FTD presents with early impairments in executive functioning, with behavioural symptoms occurring 340 at a later stage of the disease [54]. Microstate D has previously been linked to the fronto-parietal 341 network, the initial increase followed by a decline in microstate D activation may be interpreted as a 342 temporary compensatory mechanism. Studies using ML classification achieve encouraging AUC 343 values between 0.78-0.96 for bvFTD and 0.78 for PPA versus HC (see figure 4). Moral-Rubio [55]

- also discriminated between nfvPPA, svPPA and IPPA variants, with 58% accuracy.
- 346 Task based EEG

347 Only one out of 10 studies included a task-based Go/No go paradigm, showing differences in θ and δ 348 modulation related to impaired inhibition [56].



³⁴⁹

Figure 4. AUROC values in FTD studies. If multiple values were provided, only the highest value was reported. Studies

were organized according to subpopulation. bvFTD= behavioral variant Frontotemporal Dementia, FTD= Frontotemporal
 Dementia, PPA= Primary Progressive Aphasia, rsEEG=resting-state EEG, AUC= Area under the curve, Sen=sensitivity,

353 Spe= specificity, Acc= accuracy

355 Potential DLB

356 *rsEEG*

357 The most consistent finding in DLB compared to HC is slowing of the EEG pattern. More specifically, results show a leftward shift in mean dominant frequency (DF) from α range to pre- α or high- θ (6-7.5 358 359 Hz), in anterior [57], occipital [58, 59], posterior [60], or widespread areas [61]. Similarly, increased 360 power in low frequency bands [61, 62] and decreased power in high frequency bands [61], as well as decreased θ/α ratio [58], differences α/θ and α/δ ratio [60] are observed. Using the θ/α ratio, DLB 361 patients can be discriminated from HC with 76.7% sensitivity, 61.7% specificity and 66.7% accuracy 362 [63]. In DLB patients with visual hallucinations, parietal δ activity achieves 75% sensitivity, 85% 363 364 specificity, 81% accuracy in discrimination from HC. Posterior α reactivity from EC to EO is reduced in DLB, suggesting altered neural vigilance in the occipital lobe, enabling discrimination of DLB with 365 95.2% sensitivity [64]. 366

367

368 In terms of connectivity, DLB patients show consistent network disorganization. DLB was

- 369 characterized by network randomization and reduced connectivity in the α and β band [59, 65, 66]
- 370 combined with increased network complexity in the high- θ band [59]. Similarly, combining

³⁵⁴

connectivity strength of the β band with graph features of α band achieved an 76% accuracy in 371 372 differentiating DLB from HC in the study of Mehraram [67]. In terms of dynamic connectivity, DLB patients show reduced α band information flow between posterior to anterior areas [68]. Functional 373 374 source connectivity suggests cortical disconnection in DLB as both intra- and interhemispheric lagged 375 linear connectivity (LCC) in the α range are reduced. Interhemispheric LCC in α range achieves good 376 discrimination [69]. In the study of Kai [62], decreases in interhemispheric coherence (Icoh) and intrahemispheric coherence (Hcoh) were besides α also pronounced for δ , β and θ frequencies. In 377 378 terms of large-scale resting state networks (RSN), connectivity decreases are found in the visual and 379 sensorimotor network [65].

380

Two studies on microstates found contrasting results. In the study of Schumacher [70] microstate 381 382 duration of all microstates was increased with reductions in numbers of microstates per second in 383 DLB. Lamos [71] found the opposite direction of changes in prodDLB, with increased occurrence of 384 all microstates, and shorter mean duration and increased occurrence of microstate B, which is

- 385 associated with the visual network.
- 386

387 Task-based EEG

388

Three studies included a task-based EEG paradigm. One study used an auditory oddball paradigm and 389 390 found a reduced and delayed P300 amplitude, as well as a P300 latency gradient inversion in DLB [72]. A longer latency of the P300 was also found in a visual oddball task [73]. Interestingly, oddball 391 tasks reveal differences in EEG oscillations reflecting typical DLB symptoms. More specifically, DLB 392 patients show a decreased event-related δ synchronization combined with impaired α and β 393 suppression during both visual and auditory oddball tasks, and decreased θ band activity in a visual 394 395 task [73, 74]. From a clinical perspective, decreased event-related θ oscillations and decreased α suppression during a visual oddball task may serve as neurophysiological correlates of attention and 396 397 visual dysfunction in DLB. Power in δ band was able to discriminate DLB from HC with good 398 sensitivity and specificity [74].

Study	Study population	EEG acquisition	AUC/ROC	Sen	Spe	Acc
Babiloni, 2022	DLB	rsEEG	0.80	0.95	0.61	0.75
Babiloni, 2018a	DLB	rsEEG	0.78	0.84	0.65	0.74
Mehraram, 2021	DLB	rsEEG	0.82	0.59	1.00	0.76
Pascarelli, 2020	DLB VH+	rsEEG	0.85	0.75	0.85	0.81
	DLB MMSE+	rsEEG	0.70	0.77	0.62	0.67
Rosenblum, 2022	DLB	tbEEG	0.75	0.75	0.72	

³⁹⁹ 400

401 Figure 5. AUROC values in DLB studies. If multiple values were provided, only the highest value was reported. Studies 402 were alphabetically organized. DLB= Dementia with Lewy Bodies, DLB VH+= DLB with visual hallucinations, DLB 403 MMSE+= DLB with pathological Mini Mental State Examination scores, rsEEG= resting-state EEG, tbEEG= task-based 404 EEG, AUC= Area under the curve, Sen=sensitivity, Spe= specificity, Acc= accuracy.

405

406

408 Potential for discrimination

409 AD versus DLB

410 Studies comparing prodAD and prodDLB consistently find a more pronounced slowing in prodDLB 411 compared to prodAD [75–77]. To account for interindividual variability, individual α frequency peaks (IAF, maximum power peak between 6-14Hz) and transition frequency between α and θ band (TF, 412 413 minimum power density between 3-8Hz) can be used. Reduced mean TF and mean IAF values are consistent observations across DLB studies [63, 69, 70]. In the study of Babiloni [78] mean TF and 414 415 mean IAF were found to be lowered in both prodAD (m_{IAF} =8.8Hz, m_{TF} = 5.4) and prodDLB compared 416 to HC ($m_{IAF} = 9.4$ Hz, $m_{TF} = 96.3$ Hz) with more pronounced reductions in prodDLB ($m_{IAF} = 7.8$ Hz, m_{TF} 417 =4.7Hz). In the discrimination of prodAD from prodDLB, sensitivity values for spectral metrics range 418 between 41 to 78.3%, while specificity values range between 66.7 to 97% (see figure 6) [76, 78]. The 419 leftward shift in the power spectrum in DLB was also confirmed in the study of Massa [75], where α/θ 420 ratio was found to be decreased in prodDLB compared to prodAD, and in the study of Schumacher [76], where increases in θ/α ratio were correlated with more severe cases of prodDLB. In the study of 421 422 Schumacher [76], β power showed the highest AUC (0.71) in discriminating prodAD from prodDLB, with 61% sensitivity and 81% specificity. Discrimination between DLB and AD with high β power as 423 424 the most important factor, shows good sensitivity and specificity (see figure 6) [68]. Babiloni [79] found that inter- and intrahemispheric LCC values in the α band were reduced in both prodAD and 425 426 prodDLB compared to HC. While intra-hemispheric LCC α^2 was best to differentiate prodDLB from

- 427 HC, interhemispheric LCC global α^2 was best to differentiate prodAD from HC. However,
- discrimination between prodAD and prodDLB remained low (AUC <0.7). 428

429 AD versus FTD

While both FTD and AD show progressive connectivity alterations compared to HC, profound 430 frequency- and location dependent differences can be found in network organization, which are linked 431 432 to the core areas of the diseases. Compared to bvFTD, demAD patients show lower connectivity in the α and δ band in posterior regions and a widespread higher connectivity in the θ band [80]. bvFTD 433 434 patients showed an inverse pattern, with preserved posterior alpha connectivity, but lower θ activity in posterior and frontal areas. The Minimum Spanning Tree (MST) analyses indicate that frontal 435 436 networks appear to be selectively involved in bvFTD, whereas in AD, global efficiency is reduced [80]. In the study of Franctiotti [81], the typical main hub in HC is lost in FTD at dementia onset and 437 438 replaced by frontal local hubs, while network organization is largely preserved in demAD. In the same study, global clustering was able to distinguish between FTD (PPA and bvFTD) and demAD with 439 440 moderate sensitivity but high specificity (see figure 6). In the study of Bonanni [82], network 441 alterations predominantly targeted the frontal region in pFTD, while in prodAD, mutual information in 442 the left local anterior region discriminated prodFTD from prodAD with good sensitivity but low 443 specificity (see figure 6). Using the same metric, discrimination of pFTD from HC reached 89% 444 sensitivity and 90% specificity. For the discrimination of prodAD from HC, MI in the posterior 445 connections achieved high sensitivity (89-100%) and specificity (85-100%). Interestingly, these 446 effects were evident in the prodromal stages of the disease but diminished with progression, which is 447 suggestive of hyperconnectivity as a temporary compensatory mechanism to account for the effects of

448 neurodegeneration in the core areas of the specific disease.

Study	Study population	EEG acquisition	AUC/ROC	Sen	Spe	Acc
Babiloni, 2018b	prodAD vs prodDLB	rsEEG	0.72	0.78	0.67	0.73
Schumacher, 2020	prodAD vs prodDLB		0.71	0.61	0.81	
Dauwan, 2016b	DLB vs demAD	rsEEG		0.86	0.85	0.85
Bonanni, 2021	FTD (PPA&bvFTD) vs AD	rsEEG	0.71	0.89	0.44	
Franciotti, 2022	FTD(PPA&bvFTD) vs AD	rsEEG	0.80	0.67	1.00	

449 450

451 Figure 6. AUROC values in discriminative studies. If multiple values were provided, only the highest value was reported. 452 prodAD= prodromal Alzheimer's Disease, prodDLB= prodromal Dementia with Lewy Bodies, prodFTD= prodromal

453 Frontotemporal Dementia, DLB= Dementia with Lewy Bodies, demAD= dementia due to Alzheimer's Disease, PPA=

454 Primary Progressive Aphasia, bvFTD= behavioral variant Frontotemporal Dementia, rsEEG= resting-state EEG, tb-

455 EEG=task-based EEG, AUC= Area under the curve, Sen=sensitivity, Spe= specificity, Acc= accuracy.

456

457

458

Discussion

459 To the best of our knowledge, this is the first systematic review to evaluate the diagnostic utility of 460 EEG across AD, FTD, DLB as well as their preclinical and prodromal stages. The findings reveal 461 promising AUC values across diseases and disease stages, which suggest that EEG holds significant 462 diagnostic utility in AD, FTD and DLB. This, in combination with the advantages of EEG such as cost-effectiveness and non-invasiveness, could make EEG a valuable tool for the detection of 463

neurodegenerative diseases. 464

465 Potential for diagnosis of AD, FTD and DLB at the dementia stage

466 In AD, the leftward shift towards lower frequencies is a well-established finding, characterized by reductions in spectral and connectivity metrics in higher frequencies α and β , while increases in these 467 metrics are found in δ and θ bands [21–23, 25–27]. Discrimination of AD based on frequency data is 468

promising with excellent sensitivity values ranging from 88 to 93%, albeit lower specificity between 469

52-89% (see figure 3). In DLB, similar patterns of slowing arise as the most consistent findings [57-470 63, 69, 70]. Discrimination of DLB from HC using spectral metrics ranges between 75-95% 471

sensitivity, 61-85% specificity and 66.7-81% accuracy (see figure 5). Similarly, reduced connectivity 472

is found, especially within the α range [59, 62, 65–69]. Depending on the analysis, discrimination 473

474 based on connectivity measures is lower with sensitivity values of 59-84%, specificity of 65-100%,

and accuracy of 74-76% (see figure 5). Overall, the high sensitivity values suggest that frequency data 475

476 holds promise as a screening tool in both AD and DLB. 477

Preliminary studies on FTD (bvFTD and PPA) have reported varying AUC values (ranging between 478

0.69-0.96, figure 4), however, due to the heterogeneity of the FTD spectrum, the variation in analysis 479

techniques and the limited amount of studies, direct comparisons of AUC values are challenging. In 480

481 bvFTD, connectivity analysis achieves the most encouraging AUC values [51, 83]. A different

482 promising avenue could be microstate analysis, with alterations in microstate C and D, varying

perpetuity. It is made available under a CC-BY-ND 4.0 International license.

according to the subtype and stage of the disease [53, 54]. However, without ROC analysis to validate 483 484 its effectiveness, the value of microstate analysis remains uncertain.

Potential for early diagnosis 486

487 In prodAD, slowing of the frequency spectrum is the most consistent observation with slowing patterns similar to those observed in AD, with the most prominent and consistent reductions in alpha, 488 489 TF and IAF [17, 18, 20, 21, 23]. Discrimination of prodAD from MCI without AD biomarkers and HC achieves moderate sensitivity and specificity values (see figure 3). One explanation might be that 490 491 alterations in spectral metrics start before the start of preclinical AD and develop differently across 492 individuals. Recent studies have reported interindividual variability in EEG metrics, depending on the 493 degree of amyloid burden and neurodegeneration [35] as well as the interaction with other factors 494 modulating brain activity such as age [19] and education levels [18, 84].

495

485

496 Research on early stages of FTD is limited, with only one study including presymptomatic carriers of 497 a FTD causative mutation, suggesting progressive alterations in microstates [54]. More precise, the 498 upregulation of microstate D activity in the early stages of the disease might be a temporal 499 compensatory mechanism. However, as the disease progresses and the brain's capacity to maintain this 500 compensation diminishes, microstate D activity decreases. Similarly, microstate alterations have been

- 501 suggested as a potential early marker for prodDLB, with alterations inverse to those in the dementia 502 stage of the disease, which again may be explained by early maladaptive mechanisms [71].
- 503
- 504

505 Potential for differential diagnosis

506 Another key issue is the differential diagnosis of neurodegenerative diseases which is complicated due 507 to overlap in clinical symptoms and heterogeneity of the diseases. A leftward shift in the power 508 spectrum is a consistent finding in all three populations, AD [17–22], FTD [9, 50] and DLB [57–62], 509 raising questions regarding the specificity of this phenomenon. Studies comparing prodAD and 510 prodDLB consistently find a more pronounced slowing in prodDLB, with good specificity values 511 (66.7-97%) for the alpha band but low sensitivity (41-78.3%). In the study of Schumacher (2020), sensitivity values range between 23 and 61%, while specificity were higher between 81 and 89% for 512 513 different frequency bands. The high specificity across studies suggests that a significant shift in the 514 power spectrum is more likely to be indicative for prodDLB rather than prodAD. However, the low sensitivity values, indicate that in cases with less disturbed EEG patterns, differentiating between the 515 516 two becomes increasingly difficult. As the disease progresses, discrimination between DLB and AD 517 shows better sensitivity (86%) and specificity (85%) [85]. Interestingly, alterations link to the key 518 areas of the diseases. In DLB, the slowing of EEG frequencies is more pronounced in posterior regions 519 [58-60]. In FTD, reductions in alpha band are pronounced in frontal areas, which corresponds to 520 anatomical and metabolic changes in these areas in FTD patients [50]. Connectivity studies provide 521 similar evidence. In FTD, network alterations predominantly target frontal regions [80–82], aligning 522 with the progressive frontal disconnection characteristic of the disease. In contrast, more widespread 523 or posterior alterations seem to be more suggestive of AD [80, 82]. In DLB, functional connectivity is 524 reduced in the visual and sensorimotor network [65] and information flow is reduced between posterior 525 to anterior regions [68].

- 526
- 527

528 Potential of task-based versus resting state EEG

529 While resting-state EEG measures spontaneous activity, task-based EEG captures the complex

530 dynamics underlying cognitive processes that are affected in neurodegenerative diseases, thereby

increasing interpretability. Task-based paradigms offer unique insights into the neural substrates of 531

532 AD-related symptoms, showing alterations in auditory and visual target detection and memory

- 533 recognition [38, 39, 41, 45]. Notably, task-based EEG has been studied extensively in the earliest
- 534 stages of AD (figure 1c). Task-based EEG highlights early, subtle changes in neural processing of

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

memory and language preceding deficits in performance in presymptomatic FAD carriers [41–43, 49].

536 More specifically, early alterations are present in well-known ERP components N100, N200, P200 and

537P300 that are also found in prodFAD [40] and demAD [38]. Sensitivity values of task-based

paradigms identifying carriers from noncarriers range from 67-72.7% and 80-81.8% specificity (see

figure 3), which is comparable to symptomatic stages. The ability to detect early neural changes before

540 the onset of symptoms is perhaps one of the most promising findings, as it could revolutionize how we 541 approach AD.

542 Three studies in DLB employed task-basedEEG, offering insights into the neural substrates of

543 cognitive deficits in DLB. During oddball tasks, reduced and delayed P300 amplitudes are found,

relating to deficits in attention and executive functioning [72, 73]. Furthermore, DLB patients show a

545 decreased event-related δ and θ synchronization combined with impaired α and β suppression, which

546 may serve as a neurophysiological correlate of visual and attentional dysfunction in DLB showing

promising sensitivity and specificity values [73, 74]. We found no task-based studies discriminating
between neurodegenerative diseases, despite evidence of alterations in task-based analyses, such as

delayed P300 effects which have been reported in both AD [41, 45] and DLB [72, 73].

550

551

Limitations

552 The available academic literature on the diagnostic utility of EEG markers between AD, FTD and 553 DLB shows notable gaps. First, there is an underrepresentation of studies including FTD patients,

554 which limits the ability to make statements about the most promising avenue in diagnosing FTD and

discriminating FTD from other neurodegenerative diseases. Furthermore, there is a scarcity of studies

- 555 comparing across neurodegenerative diseases, which limits the ability to make statements on the 556 specificity of some markers.
- 558

559 The established heterogeneity within the AD, FTD and DLB population is thought to play a major role in the sometimes conflicting outcomes of prior research. As is shown in our review, not all disease 560 561 stages within these neurodegenerative diseases are equally represented. Studies including multiple disease stages have shown differences in the EEG markers with progression of the disease. As not all 562 563 studies describe disease duration, conflicting results might be partially explained by different disease 564 stages. On the other hand, it is clear that other factors which are hard to model in their entirety impact 565 disease presentation and severity besides disease duration. In our bias assessment, we paid special attention to the matching of confounding factors such as age and education that were studied in 566 567 multiple studies. Education has been shown to influence alpha activity, serving a neuroprotective and 568 compensatory role in AD [84]. A parallel pattern can be found between brain activity and cognitive 569 reserve (CR), the brain's resilience to neuropathology and neurodegeneration in prodAD [18]. In 570 studies using a working memory paradigm, CR translated into better neural efficiency, evidenced by 571 increased α ERD and decreased α SpecEn during high working load [47]. Taken together, these findings suggest both a compensatory mechanism in mitigating consequences of brain slowing in AD. 572 573 Finally, the impact of neuropathological co-pathology remains largely uncharted territory.

574

In terms of methodology, the variety in markers of interest, methods and analysis along with a scarcity
in reporting of AUROC values, severely limits the possibility for meta-analysis and statements about
the most promising marker. Recent work shows promise in harmonizing EEG data across centers
using novel post-processing methods [86].

579

580 The interpretation of EEG markers and their link to clinical symptoms remains largely unclear. 581 Research exploring the correlation between neural mechanisms and clinical symptoms is particularly 582 valuable in increasing the interpretability of neural alterations. For example, spectral and connectivity 583 measures may clarify the association between DLB pathology and clinical symptoms. Multiple authors 584 here measured that a shall neural deficit up dealing a here discussed [50, 65, 66]. Since particularly

have proposed that a cholinergic deficit underlies α band network alterations [59, 65, 66]. Since α oscillations are involved in thalamo- and corticocortical communication crucial for cognitive

586 processing, it is speculated that α band network alterations may connect cholinergic deficits to key

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

587 clinical symptoms in attention, perception and memory [59, 65, 66]. Finally, task-based EEG shows a 588 clear advantage to mechanistically study specific cognitive processes at the earliest disease stages, 589 when neural changes are still relatively limited. 590 591 **Conclusions and future directions** In conclusion, EEG markers show promising AUC values for detecting AD, FTD and DLB. For the 592 detection of early neural changes, task-based EEG markers are particularly valuable in identifying the 593 earliest stages of AD, revealing neurophysiological changes before clinical symptoms become 594 595 apparent. While promising sensitivity values are reported in the diagnosis of AD, FTD and DLB, the 596 specificity of these biomarkers ask for further research. The most established marker, slowing of the 597 EEG spectrum, seems to be rather a marker of neurodegeneration than specific to a certain disease. 598 However, frequency-dependent connectivity aids interpretation, illustrating disease-specific alterations 599 corresponding with the core regions and symptoms affected by each disease. Exploration of both 600 spectral metrics and microstates could be beneficial, especially with the intent towards discrimination 601 from early stages of AD, which is important for clinical application. 602 603 To reduce heterogeneity in sample sizes, future studies should strive for clear descriptions of disease 604 duration and demographic factors such as age and education levels. There is a growing body of 605 evidence illustrating the influence of interindividual variability on the onset and progression of AD. 606 Given the complex nature of disease progression, the modulatory and compensatory mechanisms of 607 these diseases should be further explored. Furthermore, future research must validate previous findings 608 in multicentric studies combining disease populations. Equally important will be the standardization of 609 research protocols, including up-to date consensus criteria, and reporting of methods allowing replication and enhancing generalizability and interpretability. 610 611 612 In conclusion, the use of EEG shows promise in diagnostic accuracy and differential diagnosis and shows advantages in non-invasiveness, availability and cost-effectiveness. With further research, the 613 search for the most optimal EEG marker could revolutionize the diagnosis of AD, FTD and DLB, 614 615 establishing an early and accurate detection of neurodegeneration. 616 617 618 619 620 621 622 623 624 625 626

Acknowledgements

SVM, TVDB, DC, PC and RB are members of the European Reference Network for Rare Neurological Diseases - Project ID No 101085584.
 No 101085584.

631

632

List of abbreviations

Ab42	Amyloid plasma
AEC	amplitude envelope correlation
AEC-c	AEC with leakage correction
AMI	Auto mutual information
ApEn	Approximate entropy
BispEn	bispectrum cubic entropy
BispMF	bispectrum median frequency
BispRP	Bispectrum relative power
CC	Clustering Coeficient
Coh	Mean global coherence
Cross-ApEn	Cross-Approximate Entropy
CSA	Compressed spectral arrays
CSD	Current Source Density
D2	Mahalanobis distance
DAR	δ to α ratio
DF	Dominant frequency
DFV	Dominant frequency variance
DRC	Dynamic Range of Connectivity
DT	Decision Tree's
DTF	directed transfer function
DWT	Discrete Wavelet Transform
EA	EEG abnormalities
ERD	Event related desynchronization
ERO	Event Related Oscillations
ERS	Event Related synchronisation
FC	Functional Connectivity
FP	Frequency Prevalence
GEV	global explained variance
GFP	Global Field Power
GMFP	Global Mean Field Power
GSA	Gready search algorithm
GTA	Graph Theory Analysis
HC	Hjorth Complexity
HHT	Hilbert Huant transform
HOFC	Higher order functional connectivity
IAC	instantaneous amplitude correlation
iCoh	Imaginary coherence
ITPC	inter-trial phase clustering
kNN	k-nearest neighbour
LDA	Linear discriminant analysis
LLC	Lagged linear coherence
LOOcv	Leave one out cross validation
LOSO	Leave one subject out (cross-validation)
LR	Logistic Regression
LZC	Lempel-Ziv Complexity
MF	Median frequency
MI	Mutual information

MSCOH	magnitude squared coherence	633
MSE	Multiscale Sample Entropy	631
MSSE	Multiscale SpecEn	034
MST	Minimum Spanning Tree	
MWC	Morlet wavelet convolution	
NB	Naive Bayes	
NCA	neighbourhood component analysis	
NDTF	non-normalized directed transfer function	
PCA	Principal Component Analysis	
PL	Path Length	
PLI	Phase Lag index	
PLV	Phase Locking Value	
PSA	Power Spectrum analysis	
PSD	Power Spectrum Density	
PSI	Phase synchronization index	
PTE	Phase Transfer Entropy	
QDA	Quadratic Dicriminant Analysis	
RCG	Revised Circular Graph	
RF	Random Forest	
RMS	Root mean square	
rMSSE	refined MSSE	
RNN	recurrent neural network	
RP	Relative Power	
RSN	Resting State Network	
SampEn	Sample Entropy	
SE	Shannon Entropy	
SMR	Stepwise multilinear regression	
SNR	Signal to noise ratio	
SP	Spectral power	
SpecEn	Spectral Entropy	
SPR	Statistical Pattern Recognition	
SR	Spectral Ratio	
SVM	Support Vector Machine	
TAR	Theta to alpha ratio	
TAS	temporal activation sequence (TAS)	
TBR	Theta to beta ratio	
TF	Transition Frequency	
wPLI	weighted PLI	
wSMI	weighted symbolic mutual information	
WT	Wavelet Transform	

635		
636		References
637 638 639	1.	Nichols E, Steinmetz JD, Vollset SE, et al (2022) Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 7:e105–e125. https://doi.org/10.1016/s2468-2667(21)00249-8
640 641	2.	Galimberti D, Scarpini E (2011) Disease-modifying treatments for Alzheimer's disease. Ther Adv Neurol Disord 4:203–216. https://doi.org/10.1177/1756285611404470
642 643 644	3.	Dubois B, Hampel H, Feldman HH, et al (2016) Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement 12:292–323. https://doi.org/10.1016/j.jalz.2016.02.002
645 646 647	4.	Cassani R, Estarellas M, San-Martin R, et al (2018) Systematic Review on Resting-State EEG for Alzheimer's Disease Diagnosis and Progression Assessment. Dis Markers 2018:1–26. https://doi.org/10.1155/2018/5174815
648 649 650	5.	Paitel ER, Samii MR, Nielson KA (2021) A systematic review of cognitive event-related potentials in mild cognitive impairment and Alzheimer's disease. Behav Brain Res 396:112904. https://doi.org/10.1016/j.bbr.2020.112904
651 652 653	6.	McKeith IG, Boeve BF, Dickson DW, et al (2017) Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 89:88–100. https://doi.org/10.1212/wnl.00000000004058
654 655 656	7.	Law ZK, Todd C, Mehraram R, et al (2020) The Role of EEG in the Diagnosis, Prognosis and Clinical Correlations of Dementia with Lewy Bodies—A Systematic Review. Diagnostics 10:616. https://doi.org/10.3390/diagnostics10090616
657 658	8.	Cromarty RA, Elder GJ, Graziadio S, et al (2016) Neurophysiological biomarkers for Lewy body dementias. Clin Neurophysiol 127:349–359. https://doi.org/10.1016/j.clinph.2015.06.020
659 660 661	9.	Lindau M, Jelic V, Johansson S-E, et al (2003) Quantitative EEG Abnormalities and Cognitive Dysfunctions in Frontotemporal Dementia and Alzheimer's Disease. Dement Geriatr Cogn Disord 15:106–114. https://doi.org/10.1159/000067973
662 663 664	10.	Caso F, Cursi M, Magnani G, et al (2012) Quantitative EEG and LORETA: valuable tools in discerning FTD from AD? Neurobiol Aging 33:2343–2356. https://doi.org/10.1016/j.neurobiolaging.2011.12.011
665 666 667	11.	Dubois B, Feldman HH, Jacova C, et al (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria. Lancet Neurol 6:734–746. https://doi.org/10.1016/s1474-4422(07)70178-3
668 669 670	12.	Dubois B, Feldman HH, Jacova C, et al (2014) Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 13:614–629. https://doi.org/10.1016/s1474-4422(14)70090-0
671 672	13.	Rascovsky K, Hodges JR, Knopman D, et al (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134:2456–2477.

673 https://doi.org/10.1093/brain/awr179

- 674 14. Gorno-Tempini ML, Hillis AE, Weintraub S, et al (2011) Classification of primary progressive
 675 aphasia and its variants. Neurology 76:1006–1014.
- 676 https://doi.org/10.1212/wnl.0b013e31821103e6
- 15. McKeith IG, Dickson DW, Lowe J, et al (2005) Diagnosis and management of dementia with
 Lewy bodies: Third report of the DLB consortium. Neurology 65:1863–1872.
 https://doi.org/10.1212/01.wnl.0000187889.17253.b1
- 680 16. Page MJ, McKenzie JE, Bossuyt PM, et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ n71. https://doi.org/10.1136/bmj.n71
- 17. Babiloni C, Del Percio C, Lizio R, et al (2017) Abnormalities of Cortical Neural Synchronization
 Mechanisms in Subjects with Mild Cognitive Impairment due to Alzheimer's and Parkinson's
 Diseases: An EEG Study. J Alzheimers Dis 59:339–358. https://doi.org/10.3233/jad-160883
- 18. Babiloni C, Ferri R, Noce G, et al (2021) Abnormalities of Cortical Sources of Resting State
 Alpha Electroencephalographic Rhythms are Related to Education Attainment in Cognitively
 Unimpaired Seniors and Patients with Alzheimer's Disease and Amnesic Mild Cognitive
 Impairment. Cereb Cortex 31:2220–2237. https://doi.org/10.1093/cercor/bhaa356
- Babiloni C, Ferri R, Noce G, et al (2021) Resting State Alpha Electroencephalographic Rhythms
 Are Differently Related to Aging in Cognitively Unimpaired Seniors and Patients with
 Alzheimer's Disease and Amnesic Mild Cognitive Impairment. J Alzheimers Dis 82:1085–1114.
 https://doi.org/10.3233/jad-201271
- 693 20. Polverino P, Ajčević M, Catalan M, et al (2022) Brain oscillatory patterns in mild cognitive
 694 impairment due to Alzheimer's and Parkinson's disease: An exploratory high-density EEG study.
 695 Clin Neurophysiol 138:1–8. https://doi.org/10.1016/j.clinph.2022.01.136
- 696 21. Cecchetti G, Agosta F, Basaia S, et al (2021) Resting-state electroencephalographic biomarkers of
 697 Alzheimer's disease. NeuroImage Clin 31:102711. https://doi.org/10.1016/j.nicl.2021.102711
- 22. Zhang H, Geng X, Wang Y, et al (2021) The Significance of EEG Alpha Oscillation Spectral
 Power and Beta Oscillation Phase Synchronization for Diagnosing Probable Alzheimer Disease.
 Front Aging Neurosci 13:. https://doi.org/10.3389/fnagi.2021.631587
- Smailovic U, Koenig T, Kåreholt I, et al (2018) Quantitative EEG power and synchronization
 correlate with Alzheimer's disease CSF biomarkers. Neurobiol Aging 63:88–95.
 https://doi.org/10.1016/j.neurobiolaging.2017.11.005
- Rodriguez R, Lopera F, Alvarez A, et al (2014) Spectral Analysis of EEG in Familial Alzheimer's
 Disease with E280A Presenilin-1 Mutation Gene. Int J Alzheimers Dis 2014:1–10. https://doi.org/10.1155/2014/180741
- Maturana-Candelas A, Gómez C, Poza J, et al (2020) Inter-band Bispectral Analysis of EEG
 Background Activity to Characterize Alzheimer's Disease Continuum. Front Comput Neurosci
 14:. https://doi.org/10.3389/fncom.2020.00070
- Prior 26. Briels CT, Schoonhoven DN, Stam CJ, et al (2020) Reproducibility of EEG functional
 connectivity in Alzheimer's disease. Alzheimers Res Ther 12:. https://doi.org/10.1186/s13195020-00632-3
- 713 27. Revilla-Vallejo M, Poza J, Gomez-Pilar J, et al (2021) Exploring the Alterations in the
 714 Distribution of Neural Network Weights in Dementia Due to Alzheimer's Disease. Entropy
 715 23:500. https://doi.org/10.3390/e23050500

- 28. Lehmann D, Ozaki H, Pal I (1987) EEG alpha map series: brain micro-states by space-oriented 716 717 adaptive segmentation. Electroencephalogr Clin Neurophysiol 67:271–288. https://doi.org/10.1016/0013-4694(87)90025-3 718
- 719 29. Lian H, Li Y, Li Y (2021) Altered EEG microstate dynamics in mild cognitive impairment and 720 Alzheimer's disease. Clin Neurophysiol 132:2861–2869. 721 https://doi.org/10.1016/j.clinph.2021.08.015
- 722 30. Smailovic U, Koenig T, Laukka EJ, et al (2019) EEG time signature in Alzheimer's disease: 723 Functional brain networks falling apart. NeuroImage Clin 24:102046. 724 https://doi.org/10.1016/j.nicl.2019.102046
- 31. Perez-Valero E, Lopez-Gordo MÁ, Gutiérrez CM, et al (2022) A self-driven approach for multi-725 726 class discrimination in Alzheimer's disease based on wearable EEG. Comput Methods Programs 727 Biomed 220:106841. https://doi.org/10.1016/j.cmpb.2022.106841
- 728 32. Perez-Valero E, Morillas C, Lopez-Gordo MA, et al (2022) An Automated Approach for the 729 Detection of Alzheimer's Disease From Resting State Electroencephalography. Front 730 Neuroinformatics 16:. https://doi.org/10.3389/fninf.2022.924547
- 33. Durongbhan P, Zhao Y, Chen L, et al (2019) A Dementia Classification Framework Using 731 732 Frequency and Time-Frequency Features Based on EEG Signals. IEEE Trans Neural Syst Rehabil Eng 27:826-835. https://doi.org/10.1109/tnsre.2019.2909100 733
- 734 34. Zhao Y, Zhao Y, Durongbhan P, et al (2020) Imaging of Nonlinear and Dynamic Functional Brain 735 Connectivity Based on EEG Recordings With the Application on the Diagnosis of Alzheimer's 736 Disease. IEEE Trans Med Imaging 39:1571–1581. https://doi.org/10.1109/tmi.2019.2953584
- 737 35. Gaubert S, Raimondo F, Houot M, et al (2019) EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease. Brain 142:2096–2112. https://doi.org/10.1093/brain/awz150 738
- 739 36. Shim Y, Yang DW, Ho S, et al (2022) Electroencephalography for Early Detection of 740 Alzheimer's Disease in Subjective Cognitive Decline. Dement Neurocognitive Disord 21:126. 741 https://doi.org/10.12779/dnd.2022.21.4.126
- 742 37. Kim NH, Yang DW, Choi SH, Kang SW (2021) Machine Learning to Predict Brain Amyloid 743 Pathology in Pre-dementia Alzheimer's Disease Using QEEG Features and Genetic Algorithm 744 Heuristic. Front Comput Neurosci 15:. https://doi.org/10.3389/fncom.2021.755499
- 745 38. Tautvydaitė D, Adam-Darqué A, Andryszak P, et al (2022) Deficient Novelty Detection and 746 Encoding in Early Alzheimer's Disease: An ERP Study. Brain Topogr 35:667-679. 747 https://doi.org/10.1007/s10548-022-00908-x
- 748 39. Stothart G, Smith LJ, Milton A, Coulthard E (2021) A passive and objective measure of recognition memory in Alzheimer's disease using Fastball memory assessment. Brain 144:2812-749 750 2825. https://doi.org/10.1093/brain/awab154
- 40. Pietto M, Parra MA, Trujillo N, et al (2016) Behavioral and Electrophysiological Correlates of 751 752 Memory Binding Deficits in Patients at Different Risk Levels for Alzheimer's Disease. J 753 Alzheimers Dis 53:1325–1340. https://doi.org/10.3233/jad-160056
- 754 41. Golob EJ, Ringman JM, Irimajiri R, et al (2009) Cortical event-related potentials in preclinical 755 familial Alzheimer disease. Neurology 73:1649–1655. 756 https://doi.org/10.1212/wnl.0b013e3181c1de77

- 757 42. Quiroz YT, Ally BA, Celone K, et al (2011) Event-related potential markers of brain changes in 758 preclinical familial Alzheimer disease. Neurology 77:469-475. https://doi.org/10.1212/wnl.0b013e318227b1b0 759
- 43. Ochoa JF, Alonso JF, Duque JE, et al (2016) Successful Object Encoding Induces Increased 760 761 Directed Connectivity in Presymptomatic Early-Onset Alzheimer's Disease. J Alzheimers Dis 762 55:1195-1205. https://doi.org/10.3233/jad-160803
- 763 44. Suárez Revelo JX, Ochoa Gomez JF, Duque Grajales JE, Tobón Quintero CA (2016) Biomarkers 764 identification in Alzheimer's disease using effective connectivity analysis from 765 electroencephalography recordings. Ing E Investig 36:50.
- https://doi.org/10.15446/ing.investig.v36n3.54037 766
- 767 45. Leko MB, Skorić MK, Klepac N, et al (2018) Event-related Potentials Improve the Efficiency of 768 Cerebrospinal Fluid Biomarkers for Differential Diagnosis of Alzheimer's Disease. Curr Alzheimer Res 15:1244–1260. https://doi.org/10.2174/1567205015666180911151116 769
- 770 46. Arakaki X, Lee R, King KS, et al (2019) Alpha desynchronization during simple working memory 771 unmasks pathological aging in cognitively healthy individuals. PLOS ONE 14:e0208517. 772 https://doi.org/10.1371/journal.pone.0208517
- 773 47. Arakaki X, Hung S-M, Rochart R, et al (2022) Alpha desynchronization during Stroop test 774 unmasks cognitively healthy individuals with abnormal CSF Amyloid/Tau. Neurobiol Aging 775 112:87-101. https://doi.org/10.1016/j.neurobiolaging.2021.11.009
- 776 48. Rochart R. Liu O. Fonteh AN, et al (2020) Compromised Behavior and Gamma Power During 777 Working Memory in Cognitively Healthy Individuals With Abnormal CSF Amyloid/Tau. Front 778 Aging Neurosci 12:. https://doi.org/10.3389/fnagi.2020.574214
- 779 49. Bobes MA, García YF, Lopera F, et al (2010) ERP generator anomalies in presymptomatic 780 carriers of the Alzheimer's disease E280A *PS-1* mutation. Hum Brain Mapp 31:247–265. 781 https://doi.org/10.1002/hbm.20861
- 782 50. Nishida K, Yoshimura M, Isotani T, et al (2011) Differences in quantitative EEG between 783 frontotemporal dementia and Alzheimer's disease as revealed by LORETA. Clin Neurophysiol 122:1718-1725. https://doi.org/10.1016/j.clinph.2011.02.011 784
- 785 51. Herzog R, Rosas FE, Whelan R, et al (2022) Genuine high-order interactions in brain networks and neurodegeneration. Neurobiol Dis 175:105918. https://doi.org/10.1016/j.nbd.2022.105918 786
- 787 52. Birba A, Fittipaldi S, Cediel Escobar JC, et al (2022) Multimodal neurocognitive markers of 788 naturalistic discourse typify diverse neurodegenerative diseases. Cereb Cortex 32:3377–3391. 789 https://doi.org/10.1093/cercor/bhab421
- 53. Nishida K, Morishima Y, Yoshimura M, et al (2013) EEG microstates associated with salience 790 791 and frontoparietal networks in frontotemporal dementia, schizophrenia and Alzheimer's disease. 792 Clin Neurophysiol 124:1106–1114. https://doi.org/10.1016/j.clinph.2013.01.005
- 793 54. Musaeus CS, Pedersen JS, Kjær TW, et al (2021) Cortical Frontoparietal Network Dysfunction in 794 CHMP2B-Frontotemporal Dementia. Front Aging Neurosci 13:. 795 https://doi.org/10.3389/fnagi.2021.714220
- 796 55. Moral-Rubio C, Balugo P, Fraile-Pereda A, et al (2021) Application of Machine Learning to 797 Electroencephalography for the Diagnosis of Primary Progressive Aphasia: A Pilot Study. Brain 798 Sci 11:1262. https://doi.org/10.3390/brainsci11101262

- 799 56. Díaz-Rivera MN, Birba A, Fittipaldi S, et al (2022) Multidimensional inhibitory signatures of 800 sentential negation in behavioral variant frontotemporal dementia. Cereb Cortex 33:403–420. https://doi.org/10.1093/cercor/bhac074 801
- 57. Franciotti R, Pilotto A, Moretti DV, et al (2020) Anterior EEG slowing in dementia with Lewy 802 803 bodies: a multicenter European cohort study. Neurobiol Aging 93:55-60. 804 https://doi.org/10.1016/j.neurobiolaging.2020.04.023
- 805 58. Jennings JL, Peraza LR, Baker M, et al (2022) Investigating the power of eyes open resting state 806 EEG for assisting in dementia diagnosis. Alzheimers Res Ther 14:. 807 https://doi.org/10.1186/s13195-022-01046-z
- 808 59. Peraza LR, Cromarty R, Kobeleva X, et al (2018) Electroencephalographic derived network 809 differences in Lewy body dementia compared to Alzheimer's disease patients. Sci Rep 8:. 810 https://doi.org/10.1038/s41598-018-22984-5
- 811 60. Bonanni L, Thomas A, Tiraboschi P, et al (2008) EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-812 813 up. Brain 131:690-705. https://doi.org/10.1093/brain/awm322
- 61. Stylianou M, Murphy N, Peraza LR, et al (2018) Quantitative electroencephalography as a marker 814 815 of cognitive fluctuations in dementia with Lewy bodies and an aid to differential diagnosis. Clin 816 Neurophysiol 129:1209-1220. https://doi.org/10.1016/j.clinph.2018.03.013
- 817 62. Kai T, Asai Y, Sakuma K, et al (2005) Quantitative electroencephalogram analysis in dementia 818 with Lewy bodies and Alzheimer's disease. J Neurol Sci 237:89–95. 819 https://doi.org/10.1016/j.jns.2005.05.017
- 820 63. Pascarelli MT, Del Percio C, De Pandis MF, et al (2020) Abnormalities of resting-state EEG in patients with prodromal and overt dementia with Lewy bodies: Relation to clinical symptoms. 821 822 Clin Neurophysiol 131:2716–2731. https://doi.org/10.1016/j.clinph.2020.09.004
- 823 64. Babiloni C, Lorenzo I, Lizio R, et al (2022) Reactivity of posterior cortical 824 electroencephalographic alpha rhythms during eves opening in cognitively intact older adults and 825 patients with dementia due to Alzheimer's and Lewy body diseases. Neurobiol Aging 115:88-826 108. https://doi.org/10.1016/j.neurobiolaging.2022.04.001
- 827 65. Aoki Y, Kazui H, Pascal-Marqui RD, et al (2019) EEG Resting-State Networks in Dementia with Lewy Bodies Associated with Clinical Symptoms. Neuropsychobiology 77:206-218. 828 829 https://doi.org/10.1159/000495620
- 66. Van Dellen E, De Waal H, Van Der Flier WM, et al (2015) Loss of EEGNetwork Efficiency Is 830 Related to Cognitive Impairment in Dementia With Lewy Bodies. Mov Disord 30:1785–1793. 831 832 https://doi.org/10.1002/mds.26309
- 67. Mehraram R, Kaiser M, Cromarty R, et al (2020) Weighted network measures reveal differences 833 834 between dementia types: An EEG study. Hum Brain Mapp 41:1573–1590. https://doi.org/10.1002/hbm.24896 835
- 836 68. Dauwan M, Van Dellen E, Van Boxtel L, et al (2016) IC-03-05: EEG Directed Connectivity from 837 Posterior Brain Regions is Decreased in Dementia with Lewy Bodies: A Comparison with 838 Alzheimer's Disease And Controls. Alzheimers Dement 12:.
- 839 https://doi.org/10.1016/j.jalz.2016.06.075

840 69. Babiloni C, Del Percio C, Lizio R, et al (2018) Abnormalities of resting-state functional cortical 841 connectivity in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study. Neurobiol Aging 65:18-40. https://doi.org/10.1016/j.neurobiolaging.2017.12.023 842 70. Schumacher J, Peraza LR, Firbank M, et al (2019) Dysfunctional brain dynamics and their origin 843 in Lewy body dementia. Brain 142:1767-1782. https://doi.org/10.1093/brain/awz069 844 845 71. Lamoš M, Morávková I, Ondráček D, et al (2021) Altered Spatiotemporal Dynamics of the 846 Resting Brain in Mild Cognitive Impairment with Lewy Bodies. Mov Disord 36:2435–2440. 847 https://doi.org/10.1002/mds.28741 848 72. Bonanni L, Franciotti R, Onofri V, et al (2010) Revisiting P300 cognitive studies for dementia diagnosis: Early dementia with Lewy bodies (DLB) and Alzheimer disease (AD). Neurophysiol 849 850 Clin Neurophysiol 40:255–265. https://doi.org/10.1016/j.neucli.2010.08.001 73. Rosenblum Y, Maidan I, Fahoum F, et al (2020) Differential changes in visual and auditory event-851 852 related oscillations in dementia with Lewy bodies. Clin Neurophysiol 131:2357–2366. https://doi.org/10.1016/j.clinph.2020.06.029 853 854 74. Rosenblum Y, Shiner T, Bregman N, et al (2022) Event-related oscillations differentiate between 855 cognitive, motor and visual impairments. J Neurol 269:3529-3540. 856 https://doi.org/10.1007/s00415-021-10953-4 857 75. Massa F, Meli R, Grazzini M, et al (2020) Utility of quantitative EEG in early Lewy body disease. 858 Parkinsonism Relat Disord 75:70-75. https://doi.org/10.1016/j.parkreldis.2020.05.007 859 76. Schumacher J, Taylor J-P, Hamilton CA, et al (2020) Quantitative EEG as a biomarker in mild 860 cognitive impairment with Lewy bodies. Alzheimers Res Ther 12:. 861 https://doi.org/10.1186/s13195-020-00650-1 862 77. Schumacher J, Taylor J-P, Hamilton CA, et al (2021) In vivo nucleus basalis of Meynert degeneration in mild cognitive impairment with Lewy bodies. NeuroImage Clin 30:102604. 863 864 https://doi.org/10.1016/j.nicl.2021.102604 78. Babiloni C, Del Percio C, Lizio R, et al (2018) Abnormalities of Resting State Cortical EEG 865 Rhythms in Subjects with Mild Cognitive Impairment Due to Alzheimer's and Lewy Body 866 867 Diseases. J Alzheimers Dis 62:247-268. https://doi.org/10.3233/jad-170703 868 79. Babiloni C, Del Percio C, Pascarelli MT, et al (2019) Abnormalities of functional cortical source 869 connectivity of resting-state electroencephalographic alpha rhythms are similar in patients with mild cognitive impairment due to Alzheimer's and Lewy body diseases. Neurobiol Aging 77:112-870 871 127. https://doi.org/10.1016/j.neurobiolaging.2019.01.013 80. Yu M, Gouw AA, Hillebrand A, et al (2016) Different functional connectivity and network 872 873 topology in behavioral variant of frontotemporal dementia and Alzheimer's disease: an EEG 874 study. Neurobiol Aging 42:150–162. https://doi.org/10.1016/j.neurobiolaging.2016.03.018 81. Franciotti R, Moretti DV, Benussi A, et al (2022) Cortical network modularity changes along the 875 876 course of frontotemporal and Alzheimer's dementing diseases. Neurobiol Aging 110:37-46. 877 https://doi.org/10.1016/j.neurobiolaging.2021.10.016 82. Bonanni L, Moretti D, Benussi A, et al (2021) Hyperconnectivity in Dementia Is Early and Focal 878 879 and Wanes with Progression. Cereb Cortex 31:97-105. https://doi.org/10.1093/cercor/bhaa209

- 83. Moguilner S, Birba A, Fittipaldi S, et al (2022) Multi-feature computational framework for 880 881 combined signatures of dementia in underrepresented settings. J Neural Eng 19:046048. https://doi.org/10.1088/1741-2552/ac87d0 882
- 84. Babiloni C, Lopez S, Del Percio C, et al (2020) Resting-state posterior alpha rhythms are 883 abnormal in subjective memory complaint seniors with preclinical Alzheimer's neuropathology 884 and high education level: the INSIGHT-preAD study. Neurobiol Aging 90:43-59. 885 https://doi.org/10.1016/j.neurobiolaging.2020.01.012 886
- 85. Dauwan M, Van Der Zande JJ, Van Dellen E, et al (2016) Random forest to differentiate dementia 887 888 with Lewy bodies from Alzheimer's disease. Alzheimers Dement Diagn Assess Dis Monit 4:99-106. https://doi.org/10.1016/j.dadm.2016.07.003 889
- 890 86. Li M, Wang Y, Lopez-Naranjo C, et al (2022) Harmonized-Multinational qEEG norms (HarMNqEEG). NeuroImage 256:119190. https://doi.org/10.1016/j.neuroimage.2022.119190 891